# Medicare Begins Coverage of GLP-1 Drugs for Weight Loss
Starting July 1, Medicare will cover GLP-1 receptor agonist medications specifically for weight loss through a new pilot program. This marks the first time the federal health program covers these drugs when prescribed solely for weight management rather than diabetes treatment.
GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) have gained widespread attention for their effectiveness in helping people lose significant amounts of weight. The medications work by mimicking hormones that regulate appetite and blood sugar. Clinical trials show patients lose 15 to 22 percent of their body weight when using these drugs combined with lifestyle changes.
The Medicare pilot will initially cover eligible beneficiaries in select geographic areas. To qualify, beneficiaries must have a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition like diabetes, high blood pressure, or sleep apnea. Participants will need to complete an initial assessment and enroll in a behavioral support program that includes diet, exercise, and counseling.
The program addresses a growing public health concern. Obesity affects roughly 42 percent of American adults, and the condition increases risk for heart disease, stroke, and type 2 diabetes. Previous Medicare policy excluded coverage for weight loss medications absent a diabetes diagnosis, leaving many older adults without access to these treatments.
Patients will still face out-of-pocket costs. The pilot requires a portion of the medication cost to be paid by beneficiaries, though specific copayment amounts vary by plan. Prescribing physicians must document clinical necessity and enroll in the program to participate.
This expansion could increase access for millions of seniors. However, drug supply constraints and ongoing prescription demand from younger patients may affect